We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cellular immunotherapies developer Carma Therapeutics has completed a venture financing round co-led by AbbVie Biotech Ventures and HealthCap in order to raise funds required to advance the development of its adoptive cellular immunotherapy named CARMA-05